FOLLOW US
inSeption Group Named a Best Places to Work Finalist by Philadelphia Business Journal for Second Consecutive Year
[Lansdale, PA] – [May 30, 2024] – inSeption Group, a leading clinical outsourcing company, is proud to announce that it has been named a finalist in the Philadelphia Business Journal’s Best Places to Work for the second consecutive year. This recognition is particularly meaningful as it is based on feedback from employee surveys, reflecting the genuine appreciation and satisfaction of the inSeption Group team.
The Best Places to Work awards celebrate companies that foster an outstanding work environment and culture, as determined by their employees. inSeption Group’s continued success in creating a supportive and inspiring workplace has been highlighted by this accolade.
“We are thrilled to be recognized as one of the Best Places to Work,” said Joe Arcangelo, co-founder of inSeption Group. “Our dedication to fostering a culture of quality, integrity, and personal accountability has brought together a group of truly exceptional individuals.”
Brian Sulpizio, co-founder of inSeption Group, added, ” This achievement is a testament to the hard work, dedication, and passion of our incredible people. At inSeption, when our employees succeed, our company succeeds, and this award reinforces our dedication to that foundational principle.”
inSeption Group continues to prioritize the professional and personal growth of its employees by offering a range of benefits, continuous learning opportunities through their proprietary initiative The Cooperativity Program™, and a collaborative work environment. As the company experiences record growth year over year, inSeption will continue to create a supportive and inclusive work environment where every team member can excel.
For more information about inSeption Group and its award-winning workplace culture, please visit inseptiongroup.com or contact Joe Arcangelo at 267-498-5092 or Brian Sulpizio at 215-855-7403.
About inSeption Group
inSeption Group is a clinical outsourcing company dedicated to providing high-quality services to the pharmaceutical and biotech industries. In the changing landscape of clinical research, we’re creating a new kind of future. One where integrity outweighs self-interest, where transparency cultivates trust, and where people deliver on their promises.
Media Contact:
Kristin Morris
Senior Director, Corporate Communications
kmorris@inseptiongroup.com
267-397-8980
870 W Main Street | Landsdale, PA
inSeption Group’s Executive Vice President, is elected Chair-Elect of the Council on Professional Registration for the Society of Quality Assurance
inSeption Group is thrilled to announce that Dawn Niccum has been designated as Chair-Elect of the Council on Professional Registration (CPR) for the Society of Quality Assurance (SQA) for the 2024 term.
“I am honored to have been elected to this position by my peers. In this role, I hope to continue to give back to SQA as it has been instrumental in supporting me in my career.”
As Chair-Elect of the CPR, Dawn will be responsible for overseeing the activities surrounding the Professional Registry credentials of Registered Quality Assurance Professionals in Good Clinical Practice (RQAP-GCP) and Registered Quality Assurance Professionals in Good Laboratory Practice (RQAP-GLP), which are recognized standards of experience and knowledge in the industry. Her leadership will undoubtedly inspire others to uphold the highest standards of quality assurance, ensuring the delivery of safe and effective treatments to patients worldwide.
At inSeption Group, Dawn has been instrumental in elevating the company’s reputation and performance in quality assurance and full-service clinical outsourcing.
According to Managing Partner Joe Arcangelo, “Dawn’s expertise has brought significant value to the inSeption Group. Not only have her contributions helped ensure inSeption’s services consistently exceed industry standards and regulatory requirements, but her deep knowledge and experience has empowered inSeption to bring innovative solutions to our industry.”
Joe further added, “We are proud of her recent election as Chair-Elect. I am certain she will be an important catalyst for increased awareness and membership by fostering collaboration, knowledge sharing, and continuous improvement, contributing to the advancement of quality assurance practices.”
About Dawn Niccum
With over 30 years of Clinical Operations, Clinical Systems, and Quality Assurance pharmaceutical experience, Dawn provides clients with a unique perspective of efficiency, speed, and compliance. She is an experienced leader in clinical compliance and auditing, inspection readiness activities, SOP development, computer system validation, quality document management, training, and safety. Her extensive experience and strength in establishing quality structures and streamlined approaches to reduce risk remains a tremendous asset in inSeption’s ability to deliver outstanding quality, best practices, efficient systems, and cost savings to our sponsors. Additionally, Dawn is recognized for her expertise in implementing TMFs across settings and systems, is a member of the CDISC TMF Reference Model Group Steering Committee and Chair of the Education Committee, is an active member of the Society of Quality Assurance and has presented as a Subject Matter Expert at numerous conferences.
About inSeption Group
inSeption Group is a full-service, global outsourcing company built on a foundational culture of exceptional service and quality. Specializing in complex trials within the oncology, rare disease, and neurodegenerative space, inSeption stands apart from traditional outsourcing options by its ability to attract and retain a subset of highly experienced and committed professionals. inSeption Group delivers quality as promised, efficiently and affordably, so that life-changing therapies can reach the patients and families who need them.
Every milestone matters for kids like Loie
If you ever need a reminder of who your hard work helps, let it be Loie.
Loie Hammond seemed like a typical toddler. She loved playing with dogs of all sizes, being outside, listening to books, making up names for her dolls, and chasing around her big brother Owen. But soon, certain behaviors began sparking questions about her development, and eventually her family was given a tragic answer.
Loie was two years old when she was diagnosed with metachromatic leukodystrophy (MLD), a rare and fatal genetic disease. Children with MLD typically exhibit normal development in their early years, but as the disease progresses, they lose the ability to walk, talk, and interact with the world around them. Like many rare diseases, treatment options were limited to symptomatic support, and most kids don’t survive their first decade. Loie didn’t live to her 4th birthday. But, thanks in part to the work done right here at inSeption, the outcome may be different for other families.
Finding purpose in the pain
Loie’s parents, Matt and Lauren, were determined to keep fighting on behalf of their daughter, and they worked closely with another MLD family to establish the Leukodystrophy Center of Excellence at the Children’s Hospital of Philadelphia in 2015—the first of its kind in the US and now the leading leukodystrophy center in the world.
inSeption Group became a part of Loie’s legacy through our work with Orchard Therapeutics. Over the course of 2+ years, the inSeption/Orchard team prepped the BLA submission for OLT-200, a gene therapy treatment for MLD. They dedicated their time, talents, and energy, tackling many challenges and complexities along the way. Matt Hammond was a consistent presence during the process, sharing Loie’s story, encouraging the team, and helping us all to remember that what we’re doing matters to other MLD families across the world.
On September 18, 2023, Orchard received the incredible news that the FDA accepted the BLA filing of OLT-200 under Priority Review. On March 18, 2024, LENMELDY™ (atidarsagene autotemcel) became the first FDA-approved gene therapy for early onset MLD. This milestone marked the culmination of countless hours of hard work and the countdown to hope for hundreds of families living with MLD.
Never forget the difference you make
Every day in every way, you are not just showing up for your colleagues, partners, or stakeholders.. You’re showing up for families like the Hammonds who are facing a devastating diagnosis and may be sitting down with their doctors at this very moment to hear their options. The inSeption team poured their hearts into the Orchard submission, and we know you all share that same level of passion for the sponsors you support. With each trial, program, and submission, we have the incredible privilege of bringing new solutions to their table.
Loie’s time came before a treatment did, but her light will live on in the future we’re building together.
Thank you for all you do and all you give. It matters.